Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy
ConditionEndometriosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-45
SponsorUniversity of Udine
About this trial
This study aims to analyze the salivary miRNA specific for patients diagnosed with endometriosis, specifically evaluating the miRNA profile of patients who respond versus those who do not respond to progestin therapy. Ninety patients attending the Chronic Pelvic Pain Clinic will be recruited, and they will be asked to provide a saliva sample before starting medical therapy. The response to the therapy will be evaluated after 4 months from the beginning of the therapy itself.
Eligibility criteria
Qualifiers
Age > 18 years
Fertile age
Clinical-ultrasound diagnosis or histological diagnosis of endometriosis
Informed consent
Disqualifiers
Pregnancy
Pre-menarcheal or post-menopausal status
Chronic pelvic pain syndrome with or without central sensitization assessed with the Central Sensitization Inventory Test (CSI)
Neoplasia, diabetes, BMI > 30 kg/m2, coagulopathies, autoimmune diseases, or other conditions that may affect salivary miRNA measurement
Trial design
Treatments tested in this trial
- Dienogest 2 MG
Treatment groups
90 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov